A better understanding of the NK cellreceptor-ligand interaction opened possibilities for new therapeuticstrategies. The well known mismatch KIR/HLA interaction is of great importance for NK cell stimulation. Lately, the interaction of the activating receptorDNAM-1 with its ligand PVR, has been highlighted in many ovarian carcinoma studies. Autologous andallogeneic NK cells, along with monoclonal antibodies, have been tested in current immunotherapies. Thisreview presents information on NK cell receptor-ligand interactions and its possibilities for NK-basedimmunotherapy against ovarian cancer.